U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT07479667) titled 'An Antibody-armored Dendritic Cell in Patients With Solid Tumors' on Feb. 08.
Brief Summary: This study is a single-arm, open-label, single-administration dose-escalation study.
Study Start Date: Feb. 05
Study Type: INTERVENTIONAL
Condition:
Solid Cancers
Adjuvant Therapy
Intervention:
BIOLOGICAL: Armored Dendritic Cell Injection
Armored dendritic cells are administered via multiple subcutaneous injections.
Recruitment Status: RECRUITING
Sponsor: Shanghai Cell Therapy Group Co.,Ltd
Published by HT Digital Content Services with permission from Health Daily Digest....